Historical valuation data is not available at this time.
Sunflower Pharmaceutical Group Co., Ltd. is a leading Chinese pharmaceutical company primarily engaged in the research and development, production, and sales of modern Chinese patent medicines and chemical drugs. The company holds a significant market position in the over-the-counter (OTC) drug segment in China, with a strong focus on pediatric, gynecological, and common cold medications. Its core products, such as 'Weixiao' series for children and 'Kanglong' series for women's health, are well-recognized brands in domestic markets. Competitive advantages include an extensive distribution network covering thousands of drugstores and medical institutions nationwide, coupled with efficient production capabilities and brand loyalty among consumers.
Focus on R&D for modernized traditional Chinese medicine (TCM); holds multiple patents for formulations and production processes
Sunflower Pharmaceutical presents a stable investment opportunity with its strong brand presence and consistent performance in the OTC drug market. However, investors should monitor regulatory changes and competitive pressures that could impact growth. The company's focus on R&D and market expansion offers potential for sustained long-term value, albeit with inherent industry risks.